EuropeanHIVHep
Meeting category
Date(s)
26 May 2021 - 28 May 2021
Meeting type
Virtual Meeting
CME credits
9
Organizer

European Meeting on HIV & Hepatitis 2021

Related Enduring Materials

Enduring Materials
Day 1 - Wednesday, 26 May 2021
Session 1: SARS-CoV-2 Variants -
Impact on Diagnostics and Treatment
Francesca Ceccherini-Silberstein, PhD
University of Rome “Tor Vergata”, Italy
Impact on Vaccine Efficacy
Session 2: Clinical Management of COVID Patients -
Update on Therapeutic Options
Roger Paredes, MD, PhD
Hospital Germans Trias & IrsiCaixa AIDS Research Institute, Spain
Long COVID
Giovanni Guaraldi, MD
University of Modena and Reggio Emilia, Italy
Session 3: Impact of COVID-19 Pandemic on People Living with HIV -
COVID-19 in People Living with HIV
Anna Maria Geretti, MD, PhD, FRCPath
University of Rome, Italy / King's College London, United Kingdom
Integrating New HIV Treatments in the COVID-19 Era
Chloe Orkin, MBChB, FRCP, MD
Queen Mary University of London, United Kingdom
Abstract - Driven Presentations -
Management of COVID-19
A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic (#1)
Andreas Chrysostomou, MSc - University of Cyprus, Cyprus
Characterization of SARS-CoV-2 Variants Circulating in Central Italy by Deep-Sequencing of Full-Length S Gene (#2)
Maria Bellocchi, University Of Rome "Tor Vergata", Italy
Molecular Epidemiology of SARS-CoV-2 in Greece Reveals Low Rates of Onward Virus Transmission After Lifting of Travel Restrictions Based on Risk Assessment During Summer 2020 (#3)
Evangelia Georgia Kostaki, PhD - Medical School, National and Kapodistrian University of Athens, Greece
High Sensitivity Pool Testing for SARS-CoV-2 RNA from Throat Wash and Nasopharyngeal Swabs (#4)
Marion Dusek - MIB, Germany
Significant SARS-CoV-2 RNA Decay During Remdesivir Treatment in Real Life COVID-19 Hospitalized Patients (#5)
Lorenzo Piermatteo, PhD - University Of Rome "Tor Vergata", Italy
Neutralization Heterogeneity of United Kingdom and South-African SARS-CoV-2 Variants in BNT162b2-Vaccinated or Convalescent COVID-19 Healthcare Workers (#6)
Stéphane Marot, MD - Hôpitaux De Paris, France
Andrea De Luca Lecture -
The Top 10 Important Observations of the Last Year Affecting Clinical Management
Valentina Svicher, PhD
University of Rome “Tor Vergata”, Italy
Day 2 - Thursday, 27 May 2021
Session 4: Long-Acting ARVs -
Prevention
Richard Elion, MD
Washington Health Institute, United States
Treatment
Rizzardini, Giuliano
Giuliano Rizzardini, MD
Luigi Sacco University Hospital, Italy
Abstract-Driven Presentations
LONG-ACTING HIV CAPSID INHIBITOR EFFECTIVE AS PREP IN A SHIV RHESUS MACAQUE MODEL (#7)
Elena Bekerman, PhD - Gilead Sciences, USA
Prevalence of Genotypic Baseline Risk Factors of of Cabotegravir+Rilpivirine Failure Among ARV-Naïve Patients (#8)
Charlotte Charpentier, PharmD, PhD - Inserm Iame U1137, France
Industry-Supported Satellite Symposia - 15:30
15:30
Satellite Symposium: New Drug Therapies – How Will We Best Use Them?
16:25
Long-acting Treatment: From Clinical Research to the Clinic
Session 5: Clinical Management of Hepatitis -
HBV - Treatment
Maria Buti, MD, PhD
Hospital General Universitari Valle Hebron, Spain
Progress and Challenges in Achieving Hepatitis B Virus Cure
Fabien Zoulim, MD, PhD
Lyon I University / Hospices Civils de Lyon / INSERM, France
Guided Poster Tour - 18:10
18:10
Discussions
Assessment of HIV-1 DNA Quantification Methods in the Italian HIV DNA Network (#28)
Dr. Ilaria Vicenti - Department of Medical Biotechnologies, University of Siena, Italy
A Multi-Allelic Molecular-Beacon-Based Real-Time RT-PCR Assay for the Detection of the Coronavirus SARS-CoV-2 from Clinical Samples (#20)
Andreas Chrysostomou, MSc - University of Cyprus, Cyprus
Epidemiology and Transmission of Drug Resistance Mutations Among Treatment-Naïve People Living with HIV-1 in Israel, 2010-2018 (#27)
Dr. Tali Wagner - Tel-Aviv University, Israel
PK-Virological Algorithm to Target Risk of Resistance Among Key Populations in Togo (#23)
Dr. Valentine Ferré - INSERM U1137, France
Day 3 - Friday, 28 May 2021
Session 6: Presentations from the Industry -
What's in the Pipeline? Presentations from Scientists from the Industry
Harmony Garges, MD, MPH
Senior Vice President, Chief Medical Officer and Head of Global Medical, ViiV Healthcare, United States
Kirsten White, PhD
Senior Director, Clinical Virology, Gilead Sciences, USA
Kathleen Squires, MD
Global Director Scientific Affairs - ID/HIV, Merck, United States
Session 7: Genetic Variations -
Interaction Subtypes and New Drugs
Charpentier, Charlotte 2021
Charlotte Charpentier PharmD, PhD
Inserm Iame U1137, France
Archived Mutations
Maria Santoro, PhD
University of Rome "Tor Vergata", Italy
Abstract-Driven Presentations
HIV-1 Subtypes B, G and CRF02_AG Transmission Cluster in Migrants Population Followed in Portugal Based on Sequence Data (#9)
Victor Pimentel - Instituto De Higiene E Medicina Tropical, Portugal
Low Prevalence of Archived M184V/I Mutations in 3 HIV-1 Suppressed, Switch Studies (#10)
Ruolan Wang - ViiV Healthcare, USA
Kinetics of Archived M184V Mutation in HIV-DNA from Highly Experienced HIV-Infected Patients with Sustained Viral Suppression (#11)
Romain Palich, MD - Pitie-Salpetriere Hospital, France
HIV-1Reverse Transcriptase Natural Polymorphism V106I Does Not Alter the Susceptibility and the Genetic Barrier to Resistance to Doravirine in Vitro (#12)
Federica Giammarino, MD - University of Siena, Italy
-
Abstracts
Virological Efficacy of Switch to 3TC/DTG in Real Life Cohort of Suppressed HIV-1 Patients with or Without Past M184V – The LAMRES Study (#13)
Maria Mercedes Santoro, PhD - University of Rome "Tor Vergata", Italy
Exploratory Analysis of Baseline Phenotypic and Genotypic Parameters in Relation to Antiviral Activity for Fostemsavir (FTR) in Heavily Treatment-Experienced (HTE) Patients in the Phase 3 BRIGHTE Study (#14)
Margaret Gartland - ViiV Healthcare, Research Triangle Park, NC, USA
Determinants of HIV-1 Late Presentation in Patients Followed in Europe (#15)
Mafalda Miranda, MD - Institute Of Hygiene And Tropical Medicine, New University Of Lisbon - Portugal
Exploration of the Possible Mechanisms Leading to Greater Mortality in People with Limited Drug Options (LDO) (#16)
Alessandro Cozzi-Lepri, MD - University College London, United Kingdom
Abstracts
Usefulness of Next-Generation Sequencing on PBMC Samples and HIV-1 DNA Quantification in Management of Treatment Optimization in HIV-1 Infected Virologically Suppressed Individuals (#17)
Daniele Armenia - Saint Camillus International University of Health Sciences, Italy
Dynamics of Total and Intact HIV-1 DNA in in Virologically Suppressed Patients Switching to DTG+3TC or ATV/r+3TC Dual Therapy (#18)
Filippo Dragoni, MD - University of Siena, Italy
APOBEC Editing in HIV DNA Proviral Vif and Pol Long-Reads Issued from Virologically-Suppressed Patients Included in the ANRS LAMIDOL Trial (#19)
Charlotte Charpentier, PharmD, PhD - Inserm Iame U1137, France
Overview
Image
EUHIVHEP
In Memoriam: Dr. Charles Boucher

We are deeply saddened to share that Dr. Charles Boucher, a member of the Organizing Committee of the European Meeting on HIV & Hepatitis 2021, has passed away after a courageous battle with cancer. Read our full memorial >

Welcome

Founded nineteen years ago as the European HIV Resistance Workshop, the European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance has evolved to embrace all aspects of the clinical care of people living with HIV in Europe. Particular emphasis is put on optimal treatment strategies, clinical virology, molecular epidemiology, and public health aspects of HIV, HBV, HCV, and emerging viruses throughout Europe.

In the last decade, the meeting has been able to capture leading clinicians and researchers from different regions of Europe. As such, this meeting is the only European platform where HIV-treating physicians and clinical virologists get together on an annual basis to present their latest research results and discuss their clinical implications in detail. 

Program Chairs 2021
General Information 
Meeting Objectives
This meeting aims to:

- Gather professionals in the fields of HIV and hepatitis clinical care and research in an interactive workshop setting

- Provide a platform for presentation and discussion of the latest developments in the field of antiviral drug development

- Map important current studies and results

- Translate new data into treatment guidelines

- Educate clinicians on how to best implement current and new drugs in clinical practice
Learning Objectives
After participating in this activity, participants will be able to:

- Summarize recent results in drug development (including most recent clinical trial results) for HIV, HBV, and HCV

- Integrate the latest scientific results into their daily clinical care to improve the quality of life of individuals living with hepatitis/HIV

- Recognize future challenges in the screening, monitoring, and diagnosis of patients living with HIV/HBV- or HCV and develop new concepts for research and care strategies
Practical Information 
Certificate of Attendance
A certificate of attendance will be sent to participants after they successfully completed the program and post-meeting survey.
Language
The official language of the meeting was English.
Translation was not provided.
Disclaimer
This meeting is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this meeting, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the meeting.
Liability and Insurance
By registering for the meeting, participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the meeting is finished, provided the speaker has given permission to do so.
Committees
Chairs 2021
Program Commitee
Organizing Committee

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the meeting, identify interesting topics and candidate speakers, and review all submitted abstracts.

Scientific Committee

The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.

  • Carlos Beltran, MD - Chilean AIDS Group, Chile
  • Marina Bobkova, PhD - Ivanovsky Institute of Virology, Russia
  • Rolf Kaiser, PhD - University of Cologne, Germany
  • Leon Kostrikis, PhD - University of Cyprus, Cyprus
  • Clive Loveday, PhD - ICVC Charitable Trust, Clinical Virology, United Kingdom
  • Monique Nijhuis, PhD - University Medical Centre Utrecht, the Netherlands
  • Milosz Parczewski, MD, PhD - Pomeranian Medical University, Poland
  • Mario Poljak, MD, PhD - Institute for Microbiology and Immunology, Slovenia
  • Gary Rubin, MD - University of Toronto, Canada
  • Maria Santoro, MD - University of Rome "Tor Vergata", Italy
  • Anders Sönnerborg, MD, PhD - Karolinska Institut, Sweden
  • Janusz Stanczak, PhD - University of Warsaw, Poland
  • Jens Verheyen, MD, PhD - Institute of Immunology and Genetics, Germany
  • David van de Vijver, PharmD PhD - Erasmus University Rotterdam, the Netherlands
  • Hauke Walter, MD - Medizinisches Labor Stendhal, Germany
  • Maurizio Zazzi, PhD - University of Siena, Italy
Support
Endorsers
Symposia
Day 2 - Thursday, 27 May 2021

This educational event has been funded by Gilead Sciences Europe Ltd who have had no involvement in the design, development or delivery of the content

New Drug Therapies – How Will We Best Use Them? - 15:30
15:30 CEST
Capsid Inhibition – a Novel Mechanism of Action
Antonella Castagna, MD
Vita-Salute San Raffaele University, Italy
15:40 CEST
Review of Lenacapavir Data Including Resistance and Clinical Pharmacology
Chloe Orkin, MBChB, FRCP, MD
Queen Mary University of London, United Kingdom
15:50 CEST
How Might Lenacapavir Best Be Implemented in Routine Clinical Care
Daniel Kuritzkes, MD
Brigham and Women's Hospital / Harvard Medical School, United States
16:00 CEST
Roundtable Discussion
Industry-Supported Promotional Satellite Symposium

Objectives:

  • To understand safety and efficacy data available on long-acting treatment
  • To identify patients suitable for long-acting treatment based on current data

This promotional satellite symposium is supported by ViiV Healthcare

Long-acting Treatment: From Clinical Research to the Clinic - 16:25
16:25 CEST
Welcome and Introduction
Gender neutral avatar
Matthew Bosse
ViiV Healthcare
16:30 CEST
Identifying Patients for Long-Acting Therapy: What We Have Learnt from Clinical Data
Antonio Antela, MD, PhD
Hospital Clínico Universitario de Santiago de Compostela, Spain
16:40 CEST
From Baseline Characteristics to Patient Selection for Long-Acting Therapy
Marta Boffito, MD, PhD, FRCP
Chelsea and Westminster Hospital London, United Kingdom
16:55 CEST
Live Panel Discussion and Closing Remarks
NX-GBL-HVX-EML-210002. May 2021
Accreditation
Accreditation Statement

The European Meeting on HIV & Hepatitis 2021 - Treatment Strategies & Antiviral Drug Resistance, Utrecht (Livestream), Netherlands, 26/05/2021-28/05/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 9 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Previous Editions
Enduring Materials Selection from European Meeting on HIV and Hepatitis 2020

Management of the COVID-19 Pandemic in Europe | Diagnostics

by Ravindra Gupta, MD, PhD from University of Cambridge, United Kingdom

Management of Viral Hepatitis

Hepatitis C Resistance: Pro-Con Debate

  • Pro - Standpoint | Francesca Ceccherini – Silberstein, PhD from University of Rome “Tor Vergata”, Italy
  • Con- Standpoint | Jean-Michel Pawlotsky, MD, PhD from University of Paris-Est, France 
Language